Cerus Q1 revenue up 23% to $59.9M, raises FY product revenue guidance

CERUS CORP

2026-Q1 EPS reported -$0.01 revenue$53,661,000

Product revenue $53.7M (+24% YoY); total revenue $59.9M (+23% YoY).
Net loss improved to $1.6M ($0.01/sh) from $7.7M ($0.04/sh) a year ago; Non-GAAP adjusted EBITDA $4.0M vs $0.2M.
Raises full-year 2026 product revenue guidance to $227M-$231M (was $224M-$228M); IFC revenue guided $22M-$24M.
Signed 4-year supply agreement with Établissement Français du Sang (EFS) for INTERCEPT Blood System and INT200.
CEO transition: COO Vivek Jayaraman to become CEO effective July 1, 2026; current CEO William Greenman to become executive chairman.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.